Hepatitis C Virus Envelope Protein E2 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Hepatitis C Virus Envelope Protein E2- Pipeline Review, H2 2019’, provides in depth analysis on Hepatitis C Virus Envelope Protein E2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Infectious Disease under development targeting Hepatitis C Virus Envelope Protein E2.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2

– The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects

– The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Ennaid Therapeutics LLC

Integrated BioTherapeutics Inc

Toray Industries Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis C Virus Envelope Protein E2 Overview

Hepatitis C Virus Envelope Protein E2 Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis C Virus Envelope Protein E2 Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis C Virus Envelope Protein E2 Companies Involved in Therapeutics Development

Ennaid Therapeutics LLC

Integrated BioTherapeutics Inc

Toray Industries Inc

Vaxart Inc

Hepatitis C Virus Envelope Protein E2 Drug Profiles

CIGB-230 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-137 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-20 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C (strain H77) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C (virus-like particle) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teslexivir Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis C Virus Envelope Protein E2 Dormant Products

Hepatitis C Virus Envelope Protein E2 Discontinued Products

Hepatitis C Virus Envelope Protein E2 Product Development Milestones

Featured News & Press Releases

Jun 04, 2018: Vaxart Reports Top line Results from Phase 2 Trial of Teslexivir for the Treatment of Condyloma

Mar 07, 2018: Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance

Nov 29, 2017: Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma

Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma

Oct 31, 2013: Results of Anaconda Pharma's Phase IIa study released

Jun 10, 2013: IBT and Stanford Awarded STTR

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Ennaid Therapeutics LLC, H2 2019

Pipeline by Integrated BioTherapeutics Inc, H2 2019

Pipeline by Toray Industries Inc, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports